[
    [
        {
            "time": "2018-10-31",
            "original_text": "格隆汇港股聚焦(10.31)︱中国建材前三季净利润升36%至104.28亿元 中国光大控股：部分高管已认购可购买公司股份的基金",
            "features": {
                "keywords": [
                    "中国建材",
                    "净利润",
                    "增长",
                    "光大控股",
                    "高管认购"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "建筑材料",
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "格隆汇港股聚焦(10.31)︱中国建材前三季净利润升36%至104.28亿元 中国光大控股：部分高管已认购可购买公司股份的基金",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-10-31",
            "original_text": "复星医药前三季度营收增17% 扣非后净增8%",
            "features": {
                "keywords": [
                    "复星医药",
                    "营收增长",
                    "净利润增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药前三季度营收增17% 扣非后净增8%",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-10-31",
            "original_text": "复星医药：控股子公司获药品临床试验申请受理",
            "features": {
                "keywords": [
                    "复星医药",
                    "临床试验",
                    "药品"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：控股子公司获药品临床试验申请受理",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-10-31",
            "original_text": "复星医药：注射用曲妥珠单抗用于转移性乳腺癌适应症治疗的III期临床研究已达到预设的主要终点",
            "features": {
                "keywords": [
                    "复星医药",
                    "曲妥珠单抗",
                    "乳腺癌",
                    "临床研究"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：注射用曲妥珠单抗用于转移性乳腺癌适应症治疗的III期临床研究已达到预设的主要终点",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-10-31",
            "original_text": "一致性评价最新进展：受理号达1536个 35个品种过评已满3家",
            "features": {
                "keywords": [
                    "一致性评价",
                    "药品审批",
                    "进展"
                ],
                "sentiment_score": 0.65,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "一致性评价最新进展：受理号达1536个 35个品种过评已满3家",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-31",
            "original_text": "带量采购倒逼制药企业创新，七成企业三季报增加研发费用",
            "features": {
                "keywords": [
                    "带量采购",
                    "制药企业",
                    "研发费用",
                    "创新"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "带量采购倒逼制药企业创新，七成企业三季报增加研发费用",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-31",
            "original_text": "【异动股】青蒿素板块拉升，海正药业(600267-CN)涨8.11%",
            "features": {
                "keywords": [
                    "青蒿素",
                    "海正药业",
                    "股价上涨"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【异动股】青蒿素板块拉升，海正药业(600267-CN)涨8.11%",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2018-10-31",
            "original_text": "医药股领涨，三季报业绩亮眼，哪些低估值高业绩标的值得关注？",
            "features": {
                "keywords": [
                    "医药股",
                    "三季报",
                    "业绩增长",
                    "低估值"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药股领涨，三季报业绩亮眼，哪些低估值高业绩标的值得关注？",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]